# US 2025/0084163 A1 · Antigen Binding Proteins That Bind ROR1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084163 A1
- Document ID: US20250084163A1
- Status: Published application
- Kind: A1
- Application number: 18/554,379
- Filed: 2022-04-08
- Published: 2025-03-13
- Earliest claimed: 2021-04-09
- Assignees: Sorrento Therapeutics, Inc.
- Applicants: Sorrento Therapeutics, Inc.
- Inventors: Heyue Zhou; Xia Cao; Lucy Lu
- Web page: https://patentgrep.com/patent/US20250084163A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides ROR1 binding proteins, particularly anti-ROR1 antibodies, or antigen-binding portions thereof, that specifically bind ROR1 and uses thereof. Various aspects of the anti-ROR1 antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-ROR1 antibodies. Methods for using the anti-ROR1 antibodies include in vitro and in vivo methods for binding ROR1, detecting ROR1 and treating diseases associated with ROR1 expression.

## Claims

### Claim 1

An anti-ROR1 antigen-binding protein or fully human anti-ROR1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region,
wherein the heavy chain variable region comprises a heavy chain complementarity determining region 1 (CDR1) a heavy chain CDR2 and a heavy chain CDR3, and the light chain variable region comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3; and
(a) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:12, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 13, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO: 14, the light chain CDR1 has the amino acid sequence of SEQ ID NO: 15, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 16, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 17; (b) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:22, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:23, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:24, the light chain CDR1 has the amino acid sequence of SEQ ID NO:25, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 26, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:27; (c) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:32, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:33, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:34, the light chain CDR1 has the amino acid sequence of SEQ ID NO:35, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 36, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:37; (d) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:42, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:43, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:44, the light chain CDR1 has the amino acid sequence of SEQ ID NO:45, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 46, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:47; (e) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:42, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:43, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:44, the light chain CDR1 has the amino acid sequence of SEQ ID NO:55, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 56, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:57.

### Claim 2 (depends on 1)

The antigen-binding protein, antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10, 20, 30 or 40, and the light chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:11, 21, 31, 41 or 51.

### Claim 3

An antigen-binding protein or fully human anti-ROR1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:10, 20, 30 or 40, and the light chain variable region having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11, 21, 31, 41 or 51.

### Claim 4

An antigen-binding protein or fully human anti-ROR1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise the amino acid sequences of SEQ ID NOS: 10 and 11, respectively (e.g., herein called RO6D8-s10), SEQ ID NOS: 20 and 21, respectively (e.g., herein called RO6D8-jlv1011), SEQ ID NOS: 30 and 31, respectively (e.g., herein called RO6D8-011), SEQ ID NOS: 40 and 41, respectively (e.g., herein called RO6A-a7gm), or SEQ ID NOS: 40 and 51, respectively (e.g., herein called RO6A-a8gm).

### Claim 5 (depends on 1, 2, 3, 4)

The antigen-binding fragment of any one of claims 1-4, comprising a Fab fragment.

### Claim 6 (depends on 1, 2, 3, 4)

The antigen-binding fragment of any one of claims 1-4, comprising a single chain antibody, wherein the heavy chain variable domain and the light chain variable domain are joined together with a peptide linker.

### Claim 7

The antigen-binding protein, antibody or antigen-binding fragment thereof, of any one of the preceding claims, comprising an IgG antibody, which is IgG1, IgG2, IgG3 or IgG4 class antibody.

### Claim 8 (depends on 7)

The antigen-binding protein, antibody or antigen-binding fragment thereof, of claim 7, comprising the IgG1 or IgG4 class antibody.

### Claim 9 (depends on 7)

The antigen-binding protein, antibody or antigen-binding fragment thereof, of claim 7, comprising the IgG1 class antibody.

### Claim 10

The antigen-binding protein, antibody or antigen-binding fragment thereof, of any one of the preceding claims, wherein the antigen-binding protein, antibody, or the antigen-binding fragment thereof, binds human ROR1 protein with a KD of 10−7 M or less.

### Claim 11

A pharmaceutical composition, comprising the antigen-binding protein, antibody or antigen-binding fragment of any one of the preceding claims and a pharmaceutically acceptable excipient.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A kit comprising the comprising the antigen-binding protein, antibody or antigen-binding fragment of any one of the preceding claims and a pharmaceutically acceptable excipient of any one of claims 1-10.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleic acid that encodes the heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment of any one of claims 1-10.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleic acid that encodes the light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment of any one of claims 1-10.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleic acid that encodes (i) the heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment of any one of claims 1-10, and (ii) the light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 16 (depends on 13)

A vector comprising the nucleic acid of claim 13.

### Claim 17 (depends on 14)

A vector comprising the nucleic acid of claim 14.

### Claim 18 (depends on 15)

A vector comprising the nucleic acid of claim 15.

### Claim 19 (depends on 16)

A host cell harboring the vector of claim 16.

### Claim 20 (depends on 19)

The host cell of claim 19, wherein the vector comprises an expression vector, and wherein the host cell expresses the heavy chain variable region.

### Claim 21 (depends on 17)

A host cell harboring the vector of claim 17.

### Claim 22 (depends on 21)

The host cell of claim 21, wherein the vector comprises an expression vector, and wherein the host cell expresses the light chain variable region.

### Claim 23 (depends on 16, 17)

A host cell harboring a first vector comprising the vector of claim 16 and a second vector comprising the vector of claim 17.

### Claim 24 (depends on 23)

The host cell of claim 23, wherein the first vector comprises a first expression vector, wherein the second vector comprises a second expression vector, and wherein the host cell expresses the heavy and the light chain variable regions.

### Claim 25 (depends on 18)

A host cell harboring the vector of claim 18.

### Claim 26 (depends on 25)

The host cell of claim 25, wherein the vector comprises an expression vector, and wherein the host cell expresses the heavy and the light chain variable regions.

### Claim 27 (depends on 20)

A method for preparing a heavy chain variable region of an antigen-binding protein, antibody or antigen-binding fragment, the method comprising: culturing a population of the host cell of claim 20 under conditions suitable for expressing the heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 28 (depends on 27)

The method of claim 27, further comprising: recovering from the host cells the expressed heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 29 (depends on 22)

A method for preparing a light chain variable region of an antigen-binding protein, antibody or antigen-binding fragment, the method comprising: culturing a population of the host cell of claim 22 under conditions suitable for expressing the light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 30 (depends on 29)

The method of claim 29, further comprising: recovering from the host cells the expressed light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 31 (depends on 24)

A method for preparing (i) a heavy chain variable region of a antigen-binding protein, antibody or antigen-binding fragment, and (ii) a light chain variable region of an antigen-binding protein, antibody or antigen-binding fragment, the method comprising: culturing a population of the host cell of claim 24 under conditions suitable for expressing (i) the heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment, and (ii) the light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 32 (depends on 31)

The method of claim 31, further comprising: recovering from the host cells (i) the expressed heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment, and (ii) the expressed light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 33 (depends on 26)

A method for preparing (i) a heavy chain variable region of an antigen-binding protein, antibody or antigen-binding fragment, and (ii) a light chain variable region of a antigen-binding protein, antibody or antigen-binding fragment, the method comprising: culturing a population of the host cell of claim 26 under conditions suitable for expressing (i) the heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment, and (ii) the light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 34 (depends on 33)

The method of claim 33, further comprising: recovering from the host cells (i) the expressed heavy chain variable region of the antigen-binding protein, antibody or antigen-binding fragment, and (ii) the expressed light chain variable region of the antigen-binding protein, antibody or antigen-binding fragment.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for inhibiting growth or proliferation of ROR1-expressing cells, comprising: contacting (i) a population of effector cells with (ii) a population of target cells which express ROR1 (iii) in the presence of the human anti-ROR1 antibody of any one of claims 1-10, under conditions that are suitable for inhibiting growth or proliferation of the ROR1-expressing cells.

### Claim 36 (depends on 35)

The method of claim 35, wherein the population of effector cells comprises PBMCs or NK cells.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein the population of target cells comprise ROR1 expressing human cancer cells or transgenic cells expressing ROR1.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the ratio of the effector-to-target cells is 1:1, 2:1, 3:1, 4:1 or 5:1.

### Claim 39 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the ratio of the effector-to-target cells is 5-10:1, 10-20:1, or 20-30:1.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for killing ROR1-expressing cells, comprising: contacting (i) a population of effector cells with (ii) a population of target cells which express ROR1 (iii) in the presence of the human anti-ROR1 antibody of any one of claims 1-10, under conditions that are suitable for inhibiting growth or proliferation of the ROR1-expressing cells.

### Claim 41 (depends on 40)

The method of claim 40, wherein the population of effector cells comprises PBMCs or NK cells.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein the population of target cells comprise ROR1 expressing human cancer cells or transgenic cells expressing ROR1.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40-42, wherein the ratio of the effector-to-target cells is 1:1, 2:1, 3:1, 4:1 or 5:1.

### Claim 44 (depends on 40, 41, 42)

The method of any one of claims 40-42, wherein the ratio of the effector-to-target cells is 5-10:1, 10-20:1, or 20-30:1.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for treating a subject having a disease associated with ROR1 expression, the method comprising: administering to the subject an effective amount of a therapeutic composition comprising the antigen-binding protein, antibody or antigen-binding fragment of any one of claims 1-10.

### Claim 46 (depends on 45)

The method of claim 45, wherein the disease associated with ROR1 expression is cancer.

### Claim 47 (depends on 46)

The method of claim 46, wherein cancer is chronic lymphocytic leukemia (CLL), breast cancer, lung cancer, gastric cancer, melanoma, colon cancer, renal cell carcinoma, or lymphomas.

### Claim 48 (depends on 46)

The method of claim 46, wherein cancer is chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic myeloid leukemia (CML), acute myeloid lymphoma (AML), myeloma, T-cell leukemia (TCL), Burkitt's lymphoma, multiple myeloma (MM), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL) that has undergone Richter's transformation, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, pancreatic cancer, osteosarcoma, head and neck cancer, ovarian cancer, breast cancer, or triple negative breast cancer (TNBC). lymphoma, small lymphocytic lymphoma, marginal cell B-cell lymphoma, renal cell carcinoma, colon cancer, colorectal cancer, epithelial squamous cell cancer, melanoma, myeloma, stomach cancer, brain cancer, lung cancer, cervical cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, or thyroid cancer.

### Claim 49 (depends on 46)

The method of claim 46, wherein the cancer is a metastatic cancer, refractory cancer, or recurrent cancer.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The antigen-binding protein, antibody or antigen-binding fragment of any one of claims 1-10, for use in the method of any one of claims 27-49.
